Member Info for travellerwj74gm

Hi BahHumbug,

Disclaimer: English is not my native language, so I used an AI tool to help translate and structure my thoughts clearly for this post. However, the analysis and critical conclusions are entirely based on my own observations from the recent Investor Meet Company presentation.I recently followed the FY26 full-year results presentation of Manolete Partners PLC

As a private investor working in the corporate legal department of a major enterprise, I have mixed feelings. While the team’s technical competence as a litigation funder is proven by their Chambers Band 1 ranking, their performance as a PLC board leaves significant room for improvement when it comes to driving shareholder value. Here is my balanced yet critical breakdown of the presentation:

1. Strategic Vagueness Over a Real RoadmapThe board announced a strategic pivot toward focusing on "large cases" to improve margins. While this makes sense in theory, the presentation lacked a concrete roadmap on how they plan to execute this differently from the status quo. Relying on the fact that they "already have great relationships with Insolvency Practitioners" is reassuring, but it is a historical strength rather than a proactive growth strategy. The outlook felt overly conservative, focusing mainly on a medium-term cash flow recovery by gradually reducing case-related credit.

2. Capital Market Approach & The Insider QuestionWhen asked about a potential delisting from the AIM market, management briefly dismissed it as "not planned". Given the high regulatory costs of maintaining a listing versus their depressed micro-cap valuation (approx. £15.8m), a more open, strategic discussion would have been justified. The same applies to their capital management: the focus was placed entirely on debt reduction without presenting a deeper economic analysis, such as weighing WACC against buying back heavily discounted shares. Regarding Insider Purchases, management historically owns a significant portion of the company. However, during the Q&A, there was a noticeable lack of commitment to new open-market purchases. If the board truly believes the current share price is severely undervalued and that recent setbacks are temporary, aggressive insider buying at these levels would be the strongest signal to send to a bleeding market. The hesitation here is concerning.

3. Operational Inefficiency and a Rigid View on AIDespite massive macroeconomic tailwinds with skyrocketing insolvencies across the UK, Manolete seems to struggle with scaling efficiently. Their administrative and staff costs appear to grow in tandem with case volumes, indicating a lack of operating leverage. Particularly disappointing was their stance on Artificial Intelligence (AI). Management stated they only use AI for basic summaries and halted wider adoption because a test by a single employee revealed "too many mistakes". From my corporate legal experience, this feels like a major red flag. While LLMs obviously require human oversight, the efficiency gains in contract drafting, legal research, and document analysis over the last two years have been monumental. Dismissing this tech based on one narrow internal test suggests Manolete remains stuck in a highly manual, traditional approach—potentially due to budget constraints regarding secure, enterprise-grade AI software.

4. The "One-Off" Fallacy: Systemic Debtor DefaultsFinancially, the Adjusted PBT landing at just £0.1m was a heavy blow, caused by a £1.8m bad debt provision after two major debtors defaulted on their settlement schedules. Management pushed these financial expectations into FY27, treating it as an isolated "one-off" anomaly. However, since Manolete’s entire business model revolves around pursuing distressed or insolvent counterparties, debtor defaults and chronic payment delays are a systemic risk inherent to the business, not a black swan event. Investors need far more comfort on how the company plans to mitigate this volatility going forward.

5. Cartel Cases: A Continued Black BoxThe long-awaited antitrust and cartel cases were brought up again as a major catalyst, but they unfortunately remain unpriceable for external shareholders. The presentation became somewhat convoluted with figures, and management quickly retreated behind Non-Disclosure Agreements (NDAs) when asked for specific timelines. Without clear visibility, it remains difficult for the market to price in this value.

An absolutely disastrous investor presentation. A fundamentally new strategy is required to generate shareholder value. In essence, this is merely a continuation of the failed strategy of the past. The board's lack of conviction is reflected in the absence of insider buying.

The only positive aspects were management's willingness to answer questions and the fact that I do believe they are genuinely striving for a turnaround.

As a shareholder, I find the persistent over-optimism of some users increasingly detached from reality. The hard figures and financial results tell a very different story—one that is accurately reflected in the current share price.

Blaming 'market sellers' or external pressure is no longer credible. The market has made a sober and accurate assessment of the situation. The time for glossy presentations and 'blue-sky' projections is over; Manolete needs to deliver tangible results now.

Regarding the independence of Canaccord Genuity’s research, here is an AI-assisted breakdown of why these reports should be taken with a grain of salt due to significant conflicts of interest:

Canaccord Genuity is the appointed Nominated Adviser (NOMAD) and sole broker for Manolete Partners plc.

Regarding the independence of the research, this means:

Paid Research: In its role as broker and NOMAD, Canaccord Genuity receives fees from Manolete for its services. The research is often classified as "Commissioned Research" or "Corporate Research." These reports are designed to increase the company's market visibility and are usually accessible to investors for free.

Conflicts of Interest: Since Canaccord Genuity is paid directly by Manolete, there is a potential conflict of interest. Analysts in these roles tend to provide more optimistic assessments than completely independent third-party analysts who have no business relationship with the company.

Regulatory Separation: Canaccord Genuity is legally required to maintain a strict separation ("Chinese Walls") between the investment banking department (which receives the money from Manolete) and the research department (which writes the analyses) to ensure objectivity.

In summary: The research is not independent in the sense of a neutral third-party opinion; rather, it is part of a paid service package for the company. While it provides valuable detailed data, it should always be read with the close business connection between Canaccord and Manolete in mind.